Stock DIMENSION THERAPEUTICS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Dimension Therapeutics Inc

Equities

US25433V1052

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”
GL
Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”
GL
Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx
GL
Dimension Therapeutics : OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors
PR
Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Shareholders to Contact the Firm for Additional Information
BU
Dimension Therapeutics Commences Patient Dosing in Global, Multi-Center Phase 1/2 Clinical Trial of DTX301 in Ornithine Transcarbamylase (OTC) Deficiency
GL
Dimension Therapeutics : REGENXBIO to Acquire Dimension Therapeutics
PU
Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Investors to Contact the Firm for Additional Information
BU
Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
GL
Dimension Therapeutics Announces Management Change
GL
Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities
GL
Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
GL
Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
GL
Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing
GL
Dimension Therapeutics to Hold Full Year 2016 Financial Results and Recent Program Updates Conference Call
GL
Newman Ferrara LLP : Announces Corporate Governance Investigation of Dimension Therapeutics Inc.
BU
Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors
GL
Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B
GL
Dimension Therapeutics Announces FDA Acceptance of Investigational New Drug Application for DTX301 to Treat OTC Deficiency
GL
Dimension Therapeutics Announces Presentation at the 58th American Society of Hematology (ASH) Annual Meeting
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Dimension Therapeutics Inc